Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial
Top Cited Papers
Open Access
- 28 February 2021
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (3), 339-348
- https://doi.org/10.1136/annrheumdis-2020-218599
Abstract
Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sjogren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. Methods Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR Sjogren's Syndrome Disease Activity Index [ESSDAI] >= 5, anti-SS-related antigen A/anti-Ro antibody positive) received weekly subcutaneous abatacept 125 mg or placebo for 169 days followed by an open-label extension to day 365. Primary endpoint was mean change from baseline in ESSDAI at day 169. Key secondary endpoints were mean change from baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and stimulated whole salivary flow (SWSF) at day 169. Other secondary clinical endpoints included glandular functions and patient-reported outcomes. Selected biomarkers and immune cell phenotypes were examined. Safety was monitored. Results Of 187 patients randomised, 168 completed double-blind period and 165 continued into open-label period. Mean (SD) baseline ESSDAI and ESSPRI total scores were 9.4 (4.3) and 6.5 (2.0), respectively. Statistical significance was not reached for primary (ESSDAI - 3.2 abatacept vs -3.7 placebo, p=0.442) or key secondary endpoints (ESSPRI, p=0.337; SWSF, p=0.584). No clinical benefit of abatacept over placebo at day 169 was seen with other clinical and PRO endpoints. Relative to baseline, abatacept was associated with significant differences vs placebo in some disease-relevant biomarkers (including IgG, IgA, IgM-rheumatoid factor) and pathogenic cell subpopulations (post hoc analyses). No new safety signals were identified. Conclusions Abatacept treatment did not result in significant clinical efficacy compared with placebo in patients with moderate-to-severe pSS, despite evidence of biological activity.Keywords
Funding Information
- Bristol-Myers Squibb Company (Not applicable)
This publication has 51 references indexed in Scilit:
- Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic AreaArthritis Care & Research, 2014
- Advances in understanding the pathogenesis of primary Sjögren's syndromeNature Reviews Rheumatology, 2013
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis & Rheumatism, 2011
- EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper CellsPublished by The American Association of Immunologists ,2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- A Simplified Quantitative Method for Assessing Keratoconjunctivitis Sicca From the Sjögren's Syndrome International RegistryAmerican Journal of Ophthalmology, 2009
- Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatmentArthritis & Rheumatism, 2007
- Role of Dendritic Cells in Sjögren's SyndromeScandinavian Journal of Immunology, 2006
- A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis siccaArthritis & Rheumatism, 2002